Securities Code: 002393 Securities Abbreviation: Lisheng Pharmaceutical Announcement Number: 2026-028 Tianjin Lisheng Pharmaceutical Co., Ltd. 2026 First Quarter Report The Company and the entire Board of Directors guarantee that the information disclosed is true, accurate, and complete, with no false records, misleading statements, or major omissions. Key Information Highlights:
- The Board of Directors, its members, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report, ensuring no false records, misleading statements, or major omissions, and assume individual and joint legal responsibility.
- The Company's principal, the person in charge of accounting, and the head of the accounting department (chief accounting officer) declare: The quarterly report's financial information is true, accurate, and complete.
- Is the first quarter financial accounting report audited? □ Yes ☑ No
I. Financial Data
(I) Key Accounting Data and Financial Indicators Does the company need to retrospectively adjust or restate previous year's accounting data? □ Yes ☑ No
| Current Reporting Period | Prior Year Period | Year-on-Year Change (%) | |
|---|---|---|---|
| Operating Revenue (RMB) | 332,282,846.72 | 369,840,643.70 | -10.16% |
| Net Profit Attributable to Shareholders of Listed Company (RMB) | 51,882,970.53 | 55,275,346.71 | -6.14% |
| Net Profit Attributable to Shareholders of Listed Company, Excluding Non-Recurring Gains and Losses (RMB) | 46,869,507.40 | 53,310,824.75 | -12.08% |
| Net Cash Flow from Operating Activities (RMB) | 988,720.31 | -977,611.58 | 201.14% |
| Basic Earnings Per Share (RMB/share) | 0.20 | 0.21 | -4.76% |
| Diluted Earnings Per Share (RMB/share) | 0.20 | 0.21 | -4.76% |
| Weighted Average Return on Equity | 1.12% | 1.14% | -0.02% |